The most severe and common adverse effect is electrolyte imbalance. Electrolyte changes reported include: Hypokalemia - 14.2% (requiring K+
supplementation 6%; with clinical symptoms 1.2%); Hypochloremia - 9.4%; Hyponatremia - 3.1%.
The other changes observed in laboratory parameters are minor and infrequent: elevation in blood uric acid (8.6%), blood glucose (6.0%), BUN (5.7%), and blood creatinine (3.6%).
CENTRAL NERVOUS SYSTEM (8.1%):
Incidence 1-3%: Asthenia, headache, dizziness, vertigo.
Incidence <1%: Drowsiness, sleepiness, insomnia, weakness, lethargy, visual disturbance.
Incidence <1%: Nausea/anorexia, dryness of mouth, gastralgia, vomiting, diarrhea, constipation.
Incidence 1-3%: Muscle cramps.
Incidence <1%: Joint pain, back pain, weakness of legs.
Incidence <1%: Orthostatic hypotension, tachycardia, ECG changes (non-specific ST-T change, U waves, left ventricular strain).
Incidence <1%: Impotence, modification of libido, polyuria.
Incidence <1%; Rash, pruritus.
Since the drug has been marketed, the following dermatological adverse effects have been rarely reported: Stevens-Johnson's syndrome, bullous eruption, photosensitivity with bullae, erythroderma, purpura. Relationship with the administration of indapamide has not been proven in all cases.
Incidence <1%; Gout.
Incidence <1%: Tinnitus, malaise/fainting, sweat.